Position in NTLA
as of Mar 31, 2026
· filed May 12, 2026
Position Value
$22,833,227
+$13,502,345 QoQ
Shares Held
1,781,063
+71.6% QoQ
Ownership
1.27%
of shares outstanding
% of Portfolio
0.12%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Sep 2025
3 quarters on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Common Shares in NTLA Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026JUPITER ASSET MANAGEMENT LTD holds $304,105,196 across 12 Biotechnology names. NTLA ranks #5 (7.5% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | HALO |
Halozyme Therapeutics, Inc.
|
1,608,256 | $103,941,584 | |
| 2 | PTCT |
Ptc Therapeutics, Inc.
|
711,457 | $48,471,564 | |
| 3 | INCY |
Incyte Corp
|
482,642 | $45,426,264 | |
| 4 | EXEL |
Exelixis, Inc.
|
967,409 | $41,492,171 | |
| 5 | NTLA |
Intellia Therapeutics, Inc.
This page
|
1,781,063 | $22,833,227 | |
| 6 | AUPH |
Aurinia Pharmaceuticals Inc.
|
803,419 | $11,906,668 | |
| 7 | ACAD |
Acadia Pharmaceuticals Inc
|
491,093 | $10,931,730 | |
| 8 | CPRX |
Catalyst Pharmaceuticals, Inc.
|
274,419 | $6,794,614 |
All Filings in NTLA
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $22,833,227 | 1,781,063 | Shares | Sole | 2026-05-12 | |
| 2025-12-31 | $9,330,882 | 1,037,918 | Shares | Defined | 2026-02-10 | |
| 2025-09-30 | $23,519,132 | 1,361,849 | Shares | Sole | 2025-11-10 | |
| No filing history on record for this holder in this stock. | ||||||